Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment

Lung Cancer. 2020 Feb:140:116-117. doi: 10.1016/j.lungcan.2019.12.004. Epub 2019 Dec 9.

Authors

Ryuya Edahiro¹, Takayuki Shiroyama², Sachiko Hijiki³, Satoshi Nojima³, Yuya Shirai¹, Shohei Koyama¹, Atsushi Kumanogoh¹

Affiliations

¹ Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
² Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan. Electronic address: takayuki.s12@hotmail.co.jp.
³ Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan.

PMID: 31848027
DOI: 10.1016/j.lungcan.2019.12.004

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents, Immunological / adverse effects*
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / immunology
Carcinoma, Squamous Cell / pathology
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / immunology
Lung Neoplasms / pathology
Lymphocytes, Tumor-Infiltrating / immunology*
Male
Myocarditis / chemically induced
Myocarditis / immunology
Myocarditis / pathology*
Nivolumab / adverse effects*
Prognosis

Substances

Antineoplastic Agents, Immunological
Nivolumab